Coherus BioSciences Inc (NAS:CHRS)
$ 1.77 0.01 (0.57%) Market Cap: 203.06 Mil Enterprise Value: 426.17 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Q4 2020 Coherus BioSciences Inc Earnings Call Transcript

Feb 24, 2021 / 09:30PM GMT
Release Date Price: $16.23 (-0.06%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Fourth Quarter and Full Year 2020 Coherus BioSciences Conference Call. (Operator Instructions)

I would now like to turn the conference over to your host today, Mr. McDavid Stilwell. Sir, please go ahead.

McDavid Stilwell
Coherus BioSciences, Inc. - EVP of Corporate Development, IR & Financial Strategy

Thank you. Good afternoon, everyone, and thank you for joining us. We issued a press release earlier announcing our 2020 fiscal year and fourth quarter results and the release can be found on the Coherus BioSciences website.

Today's call includes forward-looking statements regarding Coherus' current expectations. These statements include, but are not limited to, our ability to advance our biosimilar and immuno-oncology product candidates through development and registration. Our commercialization of UDENYCA and other potential products in the future, our ability to meet our R&D and SG&A expense guidance for 2021 as well as our uses of capital, all of which involve

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot